Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Ciprofloxacin hydrochloride Clear all

Conditions: Prostate Cancer
Interventions: UreScan; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Orange, California

Conditions: HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion
Interventions: Ciprofloxacin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Otitis Media With Effusion
Interventions: OTO-201, Sham; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Otitis Media in Patients With Tympanostomy Tubes
Interventions: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more

Conditions: Pulp Necrosis
Interventions: Double Antibiotic Paste, Triple Antibiotic Paste, Mineral Trioxide Aggregate; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 7 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Cystic Fibrosis, Chronic Bronchitis
Interventions: IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 14 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Gram-negative Bacteremia
Interventions: Intravenous Antibiotics, Oral Antibiotics; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more

Conditions: Dietary Modification
Interventions: Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin; Dietary Supplement · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stenotrophomonas Maltophilia Infection
Interventions: Antibiotic; Drug
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Conditions: Fasting
Interventions: CIPRO®XR; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Otitis Externa
Interventions: Ciprofloxacin/Dexamethasone, Ciprodex (R), Placebo; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 27
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Acute Otitis Media, AOMT
Interventions: 6 mg ciprofloxacin, 12 mg ciprofloxacin, Sham; Drug · Other
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pulp Necrosis, Regeneration
Interventions: Triple Antibiotic Paste, Standard Treatment; Drug · Other
Lead sponsor: Kenneth Hargreaves; Other
Eligibility: 6 Years to 20 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Loma Linda, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Urinary Tract Infection
Interventions: Cipro XR (Ciprofloxacin, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 33 more

Conditions: Intra Abdominal Infections
Interventions: Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more

Conditions: Infectious Diseases
Interventions: Ciprofloxacin, Non-quinolone antibiotic; Drug
Lead sponsor: Bayer; Industry
Eligibility: 2 Months to 16 Years
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 66
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more

Conditions: BK Virus Infection
Interventions: Ciprofloxacin, placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions: Single-Dose Antibiotic, Multi-Dose Antibiotic; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Uncomplicated Urinary Tract Infections
Interventions: Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tolleson, Arizona + 46 more

Conditions: Urinary Tract Infections
Interventions: Cipro XR (Ciprofloxacin, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 35
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 30 more

Conditions: Crohn Disease
Interventions: Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Fluconazole; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Otitis Media
Interventions: OTO-201 (ciprofloxacin); Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions

A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa

Dose Ranging Study of OTO-201 in AOMT

Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

Ciprofloxacin for Prevention of BK Infection

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes